Sugi Predict

Sugi Predict / Compounds / SCHEMBL1487217

SCHEMBL1487217

SCHEMBL1487217

NS(=O)(=O)C1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ CYP2C19 P33261 1/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ RAB9A P51151 2/20 0.67
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ GRIN2B Q13224 9/20 0.54
▸ HTT P42858 1/20 0.54
▸ CYP2D6 P10635 4/20 0.53
▸ CYP2C9 P11712 4/20 0.53
▸ CA1 P00915 2/20 0.51
▸ CA2 P00918 2/20 0.51
▸ CA7 P43166 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ CYP3A4 P08684 3/20 0.50
▸ F13A1 P00488 1/20 0.50
▸ TGM2 P21980 1/20 0.50
▸ TGM1 P22735 1/20 0.50
▸ ENPP2 Q13822 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21806033 0.92 SMN1; SMN2 (0.61) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL18692685 0.92 SMN1; SMN2 (0.61) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL29254531 0.89 SMN1; SMN2 (0.70) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL10297355 0.86 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL477255 0.86 SMN1; SMN2 (0.67) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL20507249 0.86 SMN1; SMN2 (0.56) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL24027195 0.85 SMN1; SMN2 (0.55) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL21806808 0.85 SMN1; SMN2 (0.55) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL15619788 0.84 SMN1; SMN2 (0.64) SMN1; SMN2CYP2C19NPC1RAB9AMEN1
SCHEMBL477390 0.83 SMN1; SMN2 (0.62) SMN1; SMN2CYP2C19NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2025-04-10 — — US disclosed
CN-118871426-A Process for preparing 1,2,3,5,6, 7-hexahydro-s-dicyclopentadiene acene derivatives 豪夫迈·罗氏有限公司 2024-10-29 — — CN disclosed
EP-4405359-A2 MDM2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-07-31 — — EP disclosed
US-11981667-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-05-14 — — US disclosed
CN-118019727-A Methods for preparing NLRP3 inhibitors 豪夫迈·罗氏有限公司 2024-05-10 — — CN disclosed
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 — — CN disclosed
WO-2023049790-A2 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-03-30 — — WO disclosed
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LTD (IE) 2023-02-02 — — US disclosed
US-11465992-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2022-10-11 — — US disclosed
EP-3978489-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS Inflazome Limited (IE) 2022-04-06 — — EP disclosed
EP-2041112-A1 NEW PYRIDINE ANALOGUES Astra Zeneca AB (SE) 2009-04-01 — — EP disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 — — WO disclosed
WO-2008101979-A1 QUINOXALINE COMPOUNDS AND USE THEREOF MERCK SERONO S.A. (CH) 2008-08-28 — — WO disclosed
US-20080096860-A1 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators ASTRAZENECA AB (SE) 2008-04-24 — — US disclosed
US-20080009523-A1 New Pyridine Analogues IV ASTRAZENECA AB (SE) 2008-01-10 — — US disclosed
WO-2008004941-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2008-01-10 — — WO disclosed
CN-101048401-A Pyrimidine sulfonamide derivatives as chemokine receptor modulators ASTRAZENECA AB (SE) 2007-10-03 — — CN disclosed
EP-1809624-A1 PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AstraZeneca AB (SE) 2007-07-25 — — EP disclosed
WO-2006024823-A9 PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-03-15 — — WO disclosed
WO-2006024823-A1 PYRIMIDINE SULPHONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2006-03-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009523-A1 New Pyridine Analogues IV P2RY12, P2RY4, P2RY11 SMN1; SMN2 3483/4885CYP2C19 201/4885NPC1 3578/4885
US-20080096860-A1 Pyrimidine Sulphonamide Derivatives as Chemokine Receptor Modulators CXCR1, CCR5, ACKR3 SMN1; SMN2 1671/4885CYP2C19 2889/4885NPC1 1171/4885
US-11981667-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, PYCARD SMN1; SMN2 2759/4885CYP2C19 338/4885NPC1 483/4885
US-20250115591-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 SMN1; SMN2 2436/4885CYP2C19 650/4885NPC1 422/4885
US-20230037255-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, NLRP1 SMN1; SMN2 2558/4885CYP2C19 581/4885NPC1 429/4885
US-11465992-B2 Sulfonamide carboxamide compounds NLRP3, NOD1, PYCARD SMN1; SMN2 2766/4885CYP2C19 358/4885NPC1 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.